XML 161 R49.htm IDEA: XBRL DOCUMENT v3.25.1
ORGANIZATION AND NATURE OF BUSINESS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 03, 2023
Jan. 06, 2023
Jan. 23, 2024
Jun. 30, 2023
Jun. 15, 2023
Apr. 24, 2023
Feb. 28, 2023
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Stockholders' equity               $ 25,951,712   $ 24,532,929 $ 36,043,028 $ 39,284,295
Accumulated deficit               (114,840,372)   (114,022,275) (91,644,233)  
Working capital               1,259,012   (296,193)    
Revenue               13,712,528 $ 14,584,473 54,426,402 53,376,874  
Net loss               (818,097) 3,868,868 (16,183,018)    
Net cash used in operations                   7,717,034    
Allowance for doubtful accounts               23,658,962   22,799,219    
Net receivable balance               528,203   534,263    
Depreciation expense               97,539 112,874      
Amortization expense               208,833 189,855 793,836 239,841  
Other Liabilities               398,838   377,264    
Impairment charge                   291,980 0  
Building Acquision [Member]                        
Cash   $ 3,950,000       $ 1,054,872            
Equity method investment aggregate cost               2,000,020   2,000,020    
Pancreta Bank [Member]                        
Investments in debt and equity securities               $ 16,666        
Share Price               $ 0.95        
Recurring Fair Value               $ 15,749        
Equity Securities               7,665        
Equity method investment aggregate cost                   7,665 8,479  
Greece [Member]                        
Revenue               $ 13,322,494 $ 14,225,572 52,935,979 $ 50,526,307  
Corporate income tax rate               22.00%        
Cash         $ 109,330              
Intangible assets         425,411              
Issuable stock amount         $ 316,081              
Shares issued         99,710              
United Kingdom [Member]                        
Corporate income tax rate               25.00%        
CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]                        
Cash       $ 873,600                
Issuable stock amount       $ 138,667           138,667    
Shares issued       46,377                
Asset acquision             $ 5,469,787          
Secured Promissory Note             $ 4,457,520          
Zip Doctor Inc [Member]                        
Cash $ 150,000                      
Payment of fees 8,788                      
Intangible assets $ 158,788                      
Impairment charge                   $ 131,032    
Cloudscreen [Member]                        
Cash     $ 317,880                  
Shares of common stock issued     280,000                  
Shares of common fair value     $ 319,200                  
Asset acquisition     $ 637,080